Brief: Shandong Boan Biotechnology Says CDE Approves Phase II Trial Of Anti-CD25 Antibody With PD-1 Inhibitor For NSCLC
02/07/2026 16:32
BRIEF-Shandong Boan Biotechnology Says CDE Approves Phase II Trial Of Anti-CD25 Antibody With PD-1 Inhibitor For NSCLC July 2 (Reuters) - Shandong Boan Biotechnology Co Ltd 6955.HK:
CDE APPROVES PHASE II TRIAL OF ANTI-CD25 ANTIBODY WITH PD-1 INHIBITOR FOR NSCLC
Further company coverage: 6955.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shandong Boan Biotechnology
See all newsBrief: Shandong Boan Biotechnology Says CDE Clears IND Application For BA1203
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil